News Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Real-time Estimate Tradegate Other stock markets 07:03:58 2024-04-25 am EDT			5-day change	1st Jan Change
2.011 ^EUR	-0.45%		+3.63%	+5.93%

Apr. 22	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI
Apr. 08	ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	Apr. 22	CI
Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat	Apr. 22	PU
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	Apr. 08	AQ
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	Apr. 08	CI
Oryzon Genomics S A : to provide corporate progress updates at several events in April	Apr. 05	PU
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023	Feb. 26	AQ
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
ORYZON to Provide Corporate Progress Updates at Several Events in February-March	Feb. 05	AQ
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024	Jan. 19	AQ
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)	Jan. 05	AQ
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder	Jan. 05	CI
ORYZON to Provide Corporate Progress Updates at Several Events in January	Jan. 03	AQ
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.	Dec. 04	AQ
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million	Nov. 21	AQ
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA	Nov. 20	CI
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug	Nov. 07	MT
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)	Nov. 07	AQ
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder	Nov. 07	CI
Oryzon Genomics S A : to provide corporate progress updates at several events in November	Nov. 06	PU
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023	23-10-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Summary

Filters